Hantracet

Quick links to important sections

Hantracet

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hantracet

Quick Facts

Property Description
Active Ingredients Acetaminophen, Tramadol Hydrochloride
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological Class Narcotic Analgesic Combination
General Purpose Management of Moderate to Moderately Severe Acute Pain
Origin Synthetic

Definition and Classification of Hantracet

Hantracet is a potent fixed-dose combination product supplied as an oral tablet for the management of pain. Pharmacologically, it is recognized as a narcotic analgesic combination, a term denoting its dual mechanism and its classification as an opioid analgesic combination that works centrally on the nervous system. This positioning in the medication landscape is for treating pain that is beyond the scope of simple, single-agent analgesics. While Hantracet is one commercial name for this specific pairing, the active ingredients are widely available globally under other trade names like Ultracet and Zaldiar in this identical formulation.

Composition and General Therapeutic Purpose

The medication's fundamental design incorporates two distinct active ingredients: Acetaminophen (a non-opioid agent) and Tramadol Hydrochloride (a centrally acting synthetic opioid analgesic). The strategic use of this dual-component structure is based on the clinical value of combining different pain-relief pathways. This drug is primarily utilized for providing effective pain management in situations of acute pain that are moderate to moderately severe. Specifically, the combination is employed when alternative, standard non-opioid pain medications have been assessed as insufficient, thus offering a step-up option in the patient's acute pain regimen.

Regulatory References

  1. DailyMed (NIH)

What side effects are possible with Hantracet?

Possible Side Effects and Safety Information

The safety profile for Hantracet is structured by regulatory documents that classify potential adverse reactions by frequency and the body system affected. These classifications are based on formal clinical study data and post-marketing surveillance.

Frequency-Classified Adverse Reactions

Adverse reactions that are formally classified as Very Common (occurring in 10% or more of patients) in official labeling include nausea, dizziness, somnolence, constipation, and headache. Reactions categorized as Common (1% to less than 10%) often affect the Gastrointestinal and Psychiatric Systems, including vomiting, dry mouth, diarrhea, anxiety, confusion, and increased sweating (hyperhidrosis). Less common events include low blood pressure, seizures, and drug dependence.

System Organ Class (SOC) Examples of Officially Listed Adverse Reactions
Gastrointestinal Nausea, Constipation, Vomiting, Dry Mouth
Nervous System Dizziness, Headache, Somnolence, Seizures (Convulsions)
Psychiatric Anxiety, Confusion, Insomnia, Drug Dependence

Serious Adverse Reactions and Safety Constraints

The regulatory label documents several serious safety considerations. These include the risk of Hepatotoxicity (severe liver damage) and the potential for Life-Threatening Respiratory Depression, particularly when treatment is initiated or the dose is increased. The official prescribing information carries a high-level safety warning concerning the risk of Addiction, Abuse, and Misuse. Additionally, safety constraints exist for specific populations; for example, increased caution is advised for older adults and use is restricted in patients with severe hepatic impairment. Prolonged use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome (NOWS).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Hantracet (a combination product containing an opioid and acetaminophen) by two distinct, life-threatening risks: respiratory and hepatic toxicity. Immediate medical attention is necessary for any suspected or accidental ingestion, particularly in children, due to the high risk of a fatal outcome, even if the individual appears well.

Documented Overdose Presentations Emergency Actions Required
Opioid Component: Profound sedation, miosis, respiratory depression (may lead to arrest), skeletal muscle flaccidity, and coma. Seizures have also been reported. Administer the opioid antagonist naloxone for respiratory depression.
Acetaminophen Component: Nausea, vomiting, diaphoresis, and malaise progressing to severe hepatic necrosis, liver failure, and death. Administer the antidote N-acetylcysteine (NAC) as soon as possible.

Urgent Medical Attention:

Immediate medical help must be sought if any signs of profound sedation, difficulty breathing, or symptoms of liver injury (e.g., vomiting, yellowing of the skin) are observed. Treatment protocols require addressing the toxicity of both components simultaneously. General supportive measures are crucial, including maintaining a patent airway and instituting controlled ventilation if needed. Monitoring involves repeated testing of vital signs and laboratory parameters to detect delayed systemic damage, with observation continuing for a specified period to assess the risk of evolving hepatotoxicity.

Therapeutic Uses of Hantracet

What Hantracet Treats: Main Uses and Benefits

The primary therapeutic use of this medication is the management of symptoms related to physical discomfort during acute episodes, often when the intensity warrants consideration of an opioid analgesic, and for which alternative treatments are deemed inadequate. This combination is utilized for managing symptomatic relief in situations characterized by **moderate to moderately severe pain intensity.

Therapeutic Scope and Benefits

The medication is applicable in conditions associated with acute or disruptive episodes, such as pain following surgical procedures, discomfort from acute trauma or injury, and pain after major dental work. It is often used in scenarios where patients experience symptoms that interfere with daily functioning and have not responded adequately to standard non-opioid options. This approach supports patients during difficult symptomatic periods by easing distress and assists with maintaining functional stability.

Quick Fact: Relief for Moderate to Moderately Severe Acute Pain

Regulatory References

  1. NIH DailyMed overview of Tramadol and Acetaminophen

Eligibility and Restrictions for Use

The official eligibility profile for Hantracet defines clear boundaries for patient use, with specific populations designated as prohibited or restricted based on age, physiological status, and underlying health conditions. The medicine is indicated for use only in adults for the short-term management of acute pain.

Contraindicated Populations

Use of Hantracet is strictly contraindicated in patients with:

  • A history of hypersensitivity to its components or other opioids.
  • Significant respiratory depression or acute/severe bronchial asthma.
  • Known gastrointestinal obstruction, including paralytic ileus.
  • Severe hepatic impairment or uncontrolled epilepsy.
  • Concurrent use of Monoamine Oxidase Inhibitors (MAOIs).

Age and Organ Function Restrictions

Population Regulatory Status
Children < 12 years Contraindicated
Adolescents < 18 Contraindicated post-tonsillectomy/adenoidectomy
Severe Renal Impairment Not Recommended
Pregnancy/Lactation Not Recommended; Prolonged use may result in Neonatal Opioid Withdrawal Syndrome.

Official labeling advises that use should be avoided in adolescents (12–18 years) who have risk factors for respiratory depression. Older adults and patients with chronic pulmonary disease require close monitoring.

What should I know about interactions with other medicines?

Hantracet carries important restrictions regarding co-administration with other medicinal products. The concomitant use of intravenous aminoglycosides is contraindicated due to the risk of potentiating their nephrotoxic effect, which could result in decreased renal function. If intravenous aminoglycoside treatment is necessary, Hantracet should be stopped and may be resumed two days after the aminoglycoside administration has been completed.

Co-administration with other nephrotoxic medicinal products is not recommended. If unavoidable, close monitoring of kidney function is advised to detect adverse changes.

Hantracet is metabolized by UGT1A9 and its exposure is decreased by strong inducers of this enzyme, such as rifampicin. Caution is necessary when combining Hantracet with medicinal products that are inducers of UGT1A9.

Based on laboratory data, Hantracet also has the potential to inhibit the transporters OAT1, OAT3, and OATP1B3. Caution is advised when Hantracet is co-administered with medicinal products that are substrates of these transporters, as it could alter their exposure. However, no dose adjustment is required when co-administered with medicinal products that are substrates of UGT1A9.

Mechanism of Action

Dual Action on Central Opioid Receptors and Monoamine Transporters

Hantracet's core mechanism involves a dual-domain approach that acts on two fundamental regulatory systems in the central nervous system. The drug functions as an agonist at mu-opioid receptors and simultaneously as an inhibitor of the norepinephrine (NET) and serotonin (SERT) transporters . This two-pronged molecular action initiates cascades that lead to widespread modulation of signal transmission.


Modulating Descending Inhibitory Pathways

The increased concentration of norepinephrine and serotonin modulates the activity of descending inhibitory pathways that project from the brainstem to the spinal cord. This mechanism is relevant in systems where targeted pathway adjustment is required to counteract signaling patterns. It results in a stronger suppression of nociceptive signal transmission, which shapes the drug's overall effect profile.


Effect on Neuronal Excitability and CNS Activity

Beyond direct signal suppression, the drug engages mechanisms that influence central neuronal excitability, with some evidence of indirect modulation of GABAA/ GABAB and NMDA systems. This affects systems where specific transmitters or mediators dominate, contributing to altered physiological responses. The resulting change in CNS activity contributes to the drug’s full profile, affecting processes of overall nervous system function.

Dosage and Administration Information

How to Use Hantracet

Hantracet is an oral medication provided as a fixed-dose tablet, which is the sole approved route of administration for this combination of Tramadol Hydrochloride and Acetaminophen. This medication is strictly designated for short-term use, with a duration limited to five days or less for the management of acute pain.


Standard Administration and Dosing

The established standard adult dosing regimen initiates treatment with two tablets per dose. This dosage, containing 75 mg of Tramadol Hydrochloride and 650 mg of Acetaminophen, is administered as needed for pain relief. Doses must be separated by a minimum of four to six hours to maintain systemic control. The maximum daily limit is set at eight tablets in any 24-hour period, which ensures the total daily intake does not exceed 300 mg of tramadol and 2,600 mg of acetaminophen. This analgesic can be taken **independently of meal times.

Usage Constraints and Adjustments

A core principle guiding the use of Hantracet is to employ the lowest effective dosage for the shortest possible duration. Furthermore, the product must never be co-administered with any other medicines containing tramadol or acetaminophen.

Specific high-level instructions apply to certain populations. For adult patients experiencing severe renal impairment, defined as a creatinine clearance of less than 30 mL/min, the maximum dosage is restricted to two tablets every 12 hours, effectively extending the dosing interval to account for reduced drug clearance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hantracet

The evidence for Hantracet (the combination of acetaminophen and tramadol) was studied for conditions characterized by different types of physical discomfort. This overview details the kinds of studies that have been conducted, what outcomes they have monitored, and the areas where the research remains limited or uncertain.


Evidence for Use in Moderate to Moderately Severe Acute Pain

Research exploring this medicine’s role in conditions associated with acute or disruptive episodes is structured around official clinical study designs, including Randomized Controlled Trials (RCTs) that are often double-blind and placebo-controlled. These studies monitored outcomes related to physical discomfort in adults who were often experiencing elevated symptoms, such as pain following surgical procedures.

Findings describe patterns observed in these studies where the combination of ingredients was associated with different measurements of physical discomfort compared to placebo. Some trials described a pattern of different measurements related to the time of reported symptom evolution with the combination formulation. These short-term studies contribute to the broader evidence landscape for patients during periods of increased symptom activity.

The evidence for acute pain remains generally limited to very short-term follow-up durations. The research provides context but research does not determine whether an individual will respond similarly for longer-term symptom patterns.


Research on Use in Other Chronic Pain Conditions

Hantracet was studied for conditions characterized by fluctuating or episodic manifestations of pain, such as Chronic Low Back Pain and pain related to Osteoarthritis. These studies often used longer follow-up durations and included various populations of adults living with chronic non-cancer pain. Research examined outcomes related to daily functioning or activity level, as well as patient-reported outcomes describing perceived discomfort.

Findings indicate that in some of these chronic conditions, patterns related to measurements of symptom intensity were observed during the study period when compared to a placebo. Findings were mixed regarding the sustained patterns observed on long-term functional and overall quality of life outcomes. The evidence is limited regarding the long-term symptom patterns of the combination in chronic conditions, as follow-up durations were often limited to intermediate-term periods.


Key Limitations and Areas of Uncertainty

The overall consistency of findings was observed in some studies to vary across trials, and some key limitations persist in the research landscape. Long-term effects are not fully established for either acute or chronic usage patterns. The follow-up durations were limited in many of the core efficacy studies. Furthermore, findings were mixed in certain chronic pain contexts, and evidence quality for outcomes related to quality of life often remains low.

Key Studies & References

  1. Tramadol Hydrochloride and Acetaminophen Tablets - FDA Approved Label and Drug Information

Frequently Asked Questions (FAQ)

Common questions about Hantracet (FAQ)


Q: Can Hantracet be used by older adults (e.g., people over 65)?

A: Official labeling for Hantracet advises increased caution and close monitoring for older adults. While the medication can be used, regulatory documents indicate that lower doses or extended time between doses may be considered in official contexts because the body's ability to clear the drug can change with age.


Q: How often is Hantracet usually taken (e.g., once a day, twice a day)?

A: The standard adult dosage is taken as needed for pain relief. Official instructions state that doses must be separated by a minimum of four to six hours. The maximum limit stated in the regulatory documents is eight tablets in any 24-hour period.


Q: Can women who are planning to become pregnant use Hantracet?

A: Hantracet is not recommended for use during pregnancy, according to official documentation. Prolonged use of medicines containing an opioid component during pregnancy is associated with the risk of the baby developing Neonatal Opioid Withdrawal Syndrome (NOWS).


Q: Is Hantracet safe to use while breastfeeding?

A: Official regulatory documents state that Hantracet is not recommended while breastfeeding. This is due to the potential for serious adverse reactions in the infant, such as respiratory depression (slowed breathing) and excessive sleepiness.


Q: Why do people say Hantracet makes them feel 'fuzzy' or sleepy?

A: Official product information for Hantracet lists somnolence (sleepiness) and dizziness as Very Common adverse reactions. These effects occur in 10% or more of patients and are Central Nervous System (CNS) effects that may be what users describe as a 'fuzzy' feeling.


Q: What should I do if I forget to take my Hantracet dose?

A: Official patient guidance for missed doses advises taking the dose if there is a sufficient amount of time until the next dose is due. If it is almost time for the next scheduled dose, the missed dose is often advised to be skipped. Patients are advised not to take two doses at the same time.


Q: Does Hantracet require a special diet or food restrictions?

A: Regulatory documents state that this analgesic can be taken independently of meal times. There are no specific food or drink restrictions, such as avoiding certain types of foods, listed in the official patient labeling.


Q: Is it true that Hantracet can cause kidney problems?

A: The official label does not state that the drug causes kidney problems in the general population. However, dosing is restricted for patients with severe renal impairment (poor kidney function) because the kidneys are responsible for clearing the drug from the body.


Q: How long does it typically take to start feeling the effect of Hantracet?

A: Clinical pharmacology studies on the drug's components indicate that the time to reach the maximum concentration in the blood is approximately 1.6 to 2.3 hours. This timeframe generally corresponds to the point at which the primary effect begins to be felt.


Q: What is the risk of dependence or addiction associated with Hantracet?

A: Official labeling carries a high-level safety warning concerning the risks of Addiction, Abuse, and Misuse. One of the active ingredients, Tramadol, is classified as a Schedule IV Controlled Substance due to its potential for dependence if not used as prescribed.


Q: Does Hantracet affect your ability to drive or operate machinery?

A: Official patient counseling information advises that Hantracet may impair mental or physical abilities necessary for performing potentially hazardous tasks. This is primarily due to side effects such as dizziness and somnolence (sleepiness).


Q: Is Hantracet safe for long-term use?

A: No. Official documents strictly designate Hantracet for short-term use only, typically limited to five days or less. Furthermore, research evidence states that the long-term effects are not fully established for this medication.


Q: Can Hantracet be crushed, cut, or chewed?

A: Official patient instructions warn that the fixed-dose tablets must be swallowed whole. Regulatory guidance advises not to chew, crush, split, or dissolve the tablets, as this could lead to a rapid release of the ingredients and a potentially serious risk.


Q: Are there different strengths or doses of Hantracet available?

A: The official product information provided describes a single fixed-dose tablet. This tablet contains a combination of 75 mg of Tramadol Hydrochloride and 650 mg of Acetaminophen.


Q: How quickly can Hantracet be stopped, or does it require gradual reduction?

A: Official guidance for opioid-containing medicines advises against abrupt discontinuation of treatment in physically-dependent patients. Regulatory guidance advises that a gradual reduction process may be used to minimize withdrawal symptoms.


Q: Is Hantracet approved for children or teenagers?

A: Hantracet is contraindicated (strictly prohibited) for children under 12 years of age. It is also contraindicated or advised to be avoided for adolescents under 18 years of age after certain surgical procedures like tonsillectomy or adenoidectomy.


Q: Can Hantracet cause changes in mood or personality?

A: Adverse reactions that affect the Psychiatric System are listed in the official documents as Common. These effects include experiences like Anxiety and Confusion.


Q: Does Hantracet have a risk evaluation and mitigation strategy (REMS)?

A: Yes. Since Hantracet contains an opioid component, it is part of the FDA-required Risk Evaluation and Mitigation Strategy (REMS) program. This program is designed to help ensure that the benefits of the drug outweigh its serious risks.


Q: Can Hantracet cause ringing in the ears (tinnitus)?

A: Official documentation for the drug’s components lists tinnitus (a sensation of ringing or noise in the ears) as one of the possible adverse reactions that has been reported.


Q: Is there a link between Hantracet and liver enzyme changes?

A: Official safety constraints list the risk of Hepatotoxicity (severe liver damage) as a major safety concern. Testing for liver enzyme changes is a standard medical method used to monitor the health of the liver.


Q: Is Hantracet considered a controlled substance?

A: Yes, Hantracet is classified as a Schedule IV controlled substance. This classification indicates the drug has an accepted medical use but also carries a potential for abuse or dependence.


Q: How long does Hantracet stay in your system after stopping treatment?

A: The length of time is described by the half-life in the drug's clinical pharmacology. The half-life for tramadol is generally around 5.6 to 7.0 hours, and the active form (metabolite) is cleared at a similar rate.

How should Hantracet be stored and disposed of?

How to Store and Dispose of Hantracet?

This medication's storage and disposal are governed by strict regulatory requirements due to its dual components, including an opioid analgesic.

Official Storage Conditions

Hantracet must be stored at Controlled Room Temperature, defined as 25°C (77°F), with allowed temperature variations between 15°C and 30°C (59°F and 86°F). The tablets must be kept in the original container and maintained tightly closed to protect the product from moisture.

Child-Safety Mandate

As required by labeling for opioid-containing products, the medicine must be stored securely and kept out of the sight and reach of children to prevent accidental, potentially fatal, overdose.

Disposal of Unused Medicine

Unused or expired product should be discarded according to official instructions for controlled substances. The preferred method is returning the medication to a drug take-back program. If a take-back program is not readily available, regulators specify that the product may be disposed of by flushing down the toilet to eliminate the immediate risk of accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hantracet found in:

A-Z Index: